AtriCure, Inc. (ATRC): Price and Financial Metrics

AtriCure, Inc. (ATRC): $23.34

0.11 (-0.47%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

ATRC Price/Volume Stats

Current price $23.34 52-week high $59.61
Prev. close $23.45 52-week low $22.42
Day low $22.87 Volume 373,207
Day high $23.69 Avg. volume 676,682
50-day MA $31.07 Dividend yield N/A
200-day MA $38.84 Market Cap 1.13B

ATRC Stock Price Chart Interactive Chart >


AtriCure, Inc. (ATRC) Company Bio


Atricure provides atrial fibrillation solutions worldwide. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The company was founded in 2000 and is based in West Chester, Ohio.


ATRC Latest News Stream


Event/Time News Detail
Loading, please wait...

ATRC Latest Social Stream


Loading social stream, please wait...

View Full ATRC Social Stream

Latest ATRC News From Around the Web

Below are the latest news stories about ATRICURE INC that investors may wish to consider to help them evaluate ATRC as an investment opportunity.

Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know

The consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Yahoo | November 15, 2023

AtriCure to Participate in the Piper Sandler 35th Annual Healthcare Conference

MASON, Ohio, November 15, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference.

Yahoo | November 15, 2023

AtriCure Releases 2023 ESG Report

MASON, Ohio, November 14, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023 Environmental, Social and Governance (ESG) Report highlighting the company’s corporate responsibility and sustainability initiatives.

Yahoo | November 14, 2023

All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy

AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | November 6, 2023

AtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call Transcript

AtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call Transcript November 1, 2023 AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.3. Operator: Good afternoon, and welcome to AtriCure’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end […]

Yahoo | November 2, 2023

Read More 'ATRC' Stories Here

ATRC Price Returns

1-mo -25.93%
3-mo -30.37%
6-mo -34.36%
1-year -44.51%
3-year -66.47%
5-year -14.00%
YTD -34.60%
2023 -19.58%
2022 -36.17%
2021 24.90%
2020 71.24%
2019 6.24%

Continue Researching ATRC

Here are a few links from around the web to help you further your research on AtriCure Inc's stock as an investment opportunity:

AtriCure Inc (ATRC) Stock Price | Nasdaq
AtriCure Inc (ATRC) Stock Quote, History and News - Yahoo Finance
AtriCure Inc (ATRC) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!